DNMT3A and acute myeloid leukemia: Since DNMT3A variants were first reported in AML in 2010, a variety of mouse modeling techniques have been used to clarify the role of DNMT3A in HSCs and the precise role that loss of function of DNMT3A plays in leukemogenesis.